NASDAQ:XTLB - X T L Biopharmaceuticals News Headlines

Sign in or create an account to add this stock to your watchlist.
$2.15 -0.23 (-9.66 %)
(As of 05/21/2019 04:00 PM ET)
Previous Close$2.38
Today's Range$2.35 - $2.35
52-Week Range$1.43 - $3.86
Volume10 shs
Average Volume1,540 shs
Market Capitalization$11.05 million
P/E Ratio3.97
Dividend YieldN/A
Beta1.01

Headlines

X T L Biopharmaceuticals (NASDAQ XTLB) News Headlines

Source:
DateHeadline
CHMP issues positive opinion for Libtayo(R) (cemiplimab) in advanced cutaneous squamous cell carcinomaCHMP issues positive opinion for Libtayo(R) (cemiplimab) in advanced cutaneous squamous cell carcinoma
www.marketwatch.com - April 27 at 10:22 AM
Winning Bounce/Lag Momentum Stocks For Week 12 Of 2019 (3/18-3/22)Winning Bounce/Lag Momentum Stocks For Week 12 Of 2019 (3/18-3/22)
seekingalpha.com - March 20 at 9:54 AM
New Data Affirms Strength of UCB Immuno-Dermatology PortfolioNew Data Affirms Strength of UCB Immuno-Dermatology Portfolio
www.prnewswire.com - March 1 at 10:48 AM
Vedanta Biosciences Initiates Phase 2 Study for Lead Rationally-Defined Bacterial Consortium Product Candidate, VE303Vedanta Biosciences Initiates Phase 2 Study for Lead Rationally-Defined Bacterial Consortium Product Candidate, VE303
www.marketwatch.com - December 17 at 10:04 AM
Model N Inc. (MODN) CEO Jason Blessing on Q4 2018 Results - Earnings Call TranscriptModel N Inc. (MODN) CEO Jason Blessing on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - November 11 at 5:18 PM
Gelesis Announces Presentations of Expanded Pivotal Data at ObesityWeek 2018Gelesis Announces Presentations of Expanded Pivotal Data at ObesityWeek 2018
www.businesswire.com - November 5 at 10:25 AM
XTL Biopharmaceuticals Reports Third Quarter 2018 Financial Results and Provides UpdateXTL Biopharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Update
finance.yahoo.com - November 1 at 4:15 PM
Galapagos NV (GLPG) CEO Onno van de Stolpe on Q3 2018 Results - Earnings Call TranscriptGalapagos NV (GLPG) CEO Onno van de Stolpe on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - October 27 at 9:56 AM
XTL Biopharmaceuticals Reports First Half 2018 Financial Results & Provides UpdateXTL Biopharmaceuticals Reports First Half 2018 Financial Results & Provides Update
finance.yahoo.com - July 24 at 10:14 AM
Merck to Present Data on Mavenclad and Rebif in Relapsing Forms of Multiple Sclerosis at EANMerck to Present Data on Mavenclad and Rebif in Relapsing Forms of Multiple Sclerosis at EAN
www.finanznachrichten.de - June 14 at 9:48 AM
XTL Biopharmaceuticals Reports First Quarter 2018 Financial Results & Provides UpdateXTL Biopharmaceuticals Reports First Quarter 2018 Financial Results & Provides Update
finance.yahoo.com - May 30 at 10:05 AM
Wired News – Medigene Announced Collaboration with RXi Pharma to Further Improve its Therapeutic T CellsWired News – Medigene Announced Collaboration with RXi Pharma to Further Improve its Therapeutic T Cells
finance.yahoo.com - December 13 at 10:51 AM
XTL Biopharmaceuticals Ltd. Regains Compliance with Nasdaqs Minimum Stockholders Equity Listing RequirementsXTL Biopharmaceuticals Ltd. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Listing Requirements
finance.yahoo.com - December 6 at 4:29 PM
XTL Biopharmaceuticals Reports Third Quarter 2017 Financial ResultsXTL Biopharmaceuticals Reports Third Quarter 2017 Financial Results
www.prnewswire.com - November 27 at 11:07 AM
XTL Biopharmaceuticals Receives Notification From NASDAQ Regarding Continuing Listing RequirementsXTL Biopharmaceuticals Receives Notification From NASDAQ Regarding Continuing Listing Requirements
finance.yahoo.com - October 24 at 12:42 PM
Corporate News Blog - Catabasis Pharma Shares Positive Results from Phase-2 MoveDMD Trials for Assessing Edasalonexent for Treatment of Duchenne Muscular DystrophyCorporate News Blog - Catabasis Pharma Shares Positive Results from Phase-2 MoveDMD Trials for Assessing Edasalonexent for Treatment of Duchenne Muscular Dystrophy
finance.yahoo.com - October 6 at 8:57 AM
Pro-Trader Daily: Earnings Review and Free Research Report: DelMar Missed Earnings ExpectationsPro-Trader Daily: Earnings Review and Free Research Report: DelMar Missed Earnings Expectations
www.finanznachrichten.de - October 5 at 2:04 PM
XTL Biopharmaceuticals Reports First Half 2017 Financial Results & Provides Clinical and Operational UpdateXTL Biopharmaceuticals Reports First Half 2017 Financial Results & Provides Clinical and Operational Update
finance.yahoo.com - October 3 at 3:53 PM
XTL Biopharma (XTLB) Reports Additional Expanded hCDR1 Preclinical Data for the Treatment of Sjogrens SyndromeXTL Biopharma (XTLB) Reports Additional Expanded hCDR1 Preclinical Data for the Treatment of Sjogren's Syndrome
www.streetinsider.com - September 12 at 12:32 PM
XTL Biopharmaceuticals Unveils Additional Expanded hCDR1 Preclinical Data for the Treatment of Sjogrens SyndromeXTL Biopharmaceuticals Unveils Additional Expanded hCDR1 Preclinical Data for the Treatment of Sjogren's Syndrome
finance.yahoo.com - September 12 at 12:32 PM
Featured Company News – Inotek Pharma Announces Top-line Results of Phase-2 FDC Trial of Trabodenoson and Offers Corporate UpdateFeatured Company News – Inotek Pharma Announces Top-line Results of Phase-2 FDC Trial of Trabodenoson and Offers Corporate Update
finance.yahoo.com - July 11 at 9:47 AM
BRIEF-XTL Biopharmaceuticals unveils expanded HCDR1 preclinical data for treatment of sjögrens syndromeBRIEF-XTL Biopharmaceuticals unveils expanded HCDR1 preclinical data for treatment of sjögren's syndrome
www.reuters.com - April 7 at 1:40 PM
XTL Biopharmaceuticals Announces $2.8 Million Private Placement From Existing InvestorsXTL Biopharmaceuticals Announces $2.8 Million Private Placement From Existing Investors
us.rd.yahoo.com - March 9 at 6:01 AM
XTL Biopharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Listing RequirementXTL Biopharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Listing Requirement
us.rd.yahoo.com - March 3 at 7:54 AM
8:34 am XTL Biopharma to effect on February 10, 2017 a change in the ratio from one Depositary Share representing twenty ordinary shares to a new ratio of one depositary share representing one hundred ordinary shares8:34 am XTL Biopharma to effect on February 10, 2017 a change in the ratio from one Depositary Share representing twenty ordinary shares to a new ratio of one depositary share representing one hundred ordinary shares
us.rd.yahoo.com - January 27 at 4:16 PM
XTL Biopharmaceuticals Announces Ratio Change of its Depositary Receipt ProgramXTL Biopharmaceuticals Announces Ratio Change of its Depositary Receipt Program
www.prnewswire.com - January 26 at 6:38 AM
XTL Biopharma (XTLB) Announces Receipt of NASDAQ Notification Regarding Minimum Bid RequirementsXTL Biopharma (XTLB) Announces Receipt of NASDAQ Notification Regarding Minimum Bid Requirements
www.streetinsider.com - November 10 at 12:16 PM
XTL Biopharmaceuticals Lupus Drug hCDR1 Granted Patent for Pharmaceutical Composition & Manufacturing ProcessesXTL Biopharmaceuticals' Lupus Drug hCDR1 Granted Patent for Pharmaceutical Composition & Manufacturing Processes
feeds.benzinga.com - February 10 at 9:43 AM
4 Speculative Biotechs With Huge Analyst Targets4 Speculative Biotechs With Huge Analyst Targets
247wallst.com - May 9 at 9:45 AM
This page was last updated on 5/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel